Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections
Science Translational Medicine · 04.11.2026 · 18 (874)
DOI: 10.1126/scitranslmed.aec3480 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Science Translational Medicine, erschienen am 04.11.2026. Verfasst von Allan C deCamp und 49 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Antibodies, Monoclonal. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The two parallel antibody-mediated prevention (AMP) efficacy trials evaluated whether intravenous infusion of the anti-CD4 binding site broadly neutralizing antibody VRC01 prevents HIV-1 acquisition. Here, we analyzed HIV-1 acquisition in AMP through the week 104 final study visit. Against viruses considered highly sensitive to VRC01 [80% inhibitory concentration (IC 80 ) < 1 microgram/milliliter], VRC01 prophylaxis maintained cumulative prevention efficacy of 66.3% (95% confidence interval: 32.4, 83.2%), suggesting that the antibody successfully blocked or cleared these infections. In the post–week 80 period (after the final dose at week 72), HIV diagnosis and resistance to VRC01 were more frequent and greater in the VRC01 groups versus placebo. For instance, more HIV diagnoses with viruses considered moderately sensitive or resistant to VRC01 (IC 80 ≥ 5 microgram/milliliter) were made in the VRC01 groups compared with placebo groups (11 versus 1). Plausibly, as in vivo VRC01 concentration waned, suppressed viruses—often evolving greater resistance because of selective pressure—emerged as detectable infections. Our findings suggest that, whereas single antibodies can block sensitive strains, multiple antibodies are likely required to prevent both viral escape and breakthrough infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA.
- Biostatistics Division, Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
- US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
- Department of Global Health, University of Washington, Seattle, WA, USA.
ORCID-Profile: Allan C deCamp, Michal Juraska, Li Li, Craig A Magaret, Brian D Williamson, Hongjun Bai, Yunda Huang, Elena E Giorgi, Lindsay N Carpp, Srilatha Edupuganti, Pedro Gonzales, Robinson Cabello, Catherine Orrell, Javier R Lama, Fatima Laher, Erica M Lazarus, Jorge Sanchez, Ian Frank, Magdalena E Sobieszczyk, Pamela G Mukwekwerere, Kelly E Seaton, M Juliana McElrath, Simbarashe Takuva, April K Randhawa, Estelle Piwowar-Manning, Deborah J Donnell, Nirupama Sista, Shelly T Karuna, James G Kublin, Glenda E Gray, Myron S Cohen, Dan H Barouch, Georgia D Tomaras, Morgane Rolland, David C Montefiori, Lynn Morris, Carolyn Williamson, Lawrence Corey, Peter B Gilbert
Förderung
- NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- Henry M. Jackson Foundation
Zitieren
APA
deCamp, A. C., Juraska, M., Li, L., Magaret, C. A., Williamson, B. D., Bai, H., Huang, Y., Giorgi, E. E., Zhang, L., Carpp, L. N., Edupuganti, S., Mgodi, N. M., Gillespie, K., Haddock, B., Gonzales, P., Cabello, R., Orrell, C., Lama, J. R., Laher, F., …, & Gilbert, P. B. (2026). Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections. Science Translational Medicine, 18(874). https://doi.org/10.1126/scitranslmed.aec3480
Vancouver
deCamp AC, Juraska M, Li L, Magaret CA, Williamson BD, Bai H, et al. Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections. Science Translational Medicine. 2026;18(874). doi:10.1126/scitranslmed.aec3480
BibTeX
@article{deCamp2026,
author = {deCamp, Allan C and Juraska, Michal and Li, Li and Magaret, Craig A and Williamson, Brian D and Bai, Hongjun and Huang, Yunda and Giorgi, Elena E and Zhang, Lily and Carpp, Lindsay N and Edupuganti, Srilatha and Mgodi, Nyaradzo M and Gillespie, Kevin and Haddock, Beatrix and Gonzales, Pedro and Cabello, Robinson and Orrell, Catherine and Lama, Javier R and Laher, Fatima and Lazarus, Erica M and Sanchez, Jorge and Frank, Ian and Hinojosa, Juan C and Sobieszczyk, Magdalena E and Mukwekwerere, Pamela G and Makhema, Joseph and Baden, Lindsey R and Seaton, Kelly E and Hural, John and McElrath, M Juliana and Takuva, Simbarashe and Randhawa, April K and Kochar, Nidhi and Piwowar-Manning, Estelle and Donnell, Deborah J and Sista, Nirupama and Andrew, Philip and Karuna, Shelly T and Kublin, James G and Gray, Glenda E and Cohen, Myron S and Barouch, Dan H and Tomaras, Georgia D and Rolland, Morgane and Montefiori, David C and Morris, Lynn and Mullins, James I and Williamson, Carolyn and Corey, Lawrence and Gilbert, Peter B},
title = {Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections},
journal = {Science Translational Medicine},
year = {2026},
volume = {18},
number = {874},
doi = {10.1126/scitranslmed.aec3480}
}
EUVIMED